Fisetin and DHA Combination for Bone Loss Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for osteoporosis and bone-related disorders are limited, with hormone replacement therapy no longer recommended as first-line therapy, and existing nutritional prevention strategies relying solely on calcium/vitamin D supplementation, leading to a need for alternative, side-effect-free, and cost-effective solutions for preventing and treating bone loss and osteoporosis.
Innovation Solution
A combination of fisetin and DHA, or its derivatives in the form of glycerides or phospholipids, is used to inhibit bone loss and stimulate bone formation, offering a synergistic action that inhibits osteoclast differentiation and promotes osteoblast activity, thus addressing imbalances in bone formation and resorption.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hormone replacement therapy is used to treat osteoporosis, then bone loss is reduced, but side effects increase and it is no longer recommended as first-line therapy
Solution Approach 1:
The patent replaces expensive, long-term hormone replacement therapy with a natural, short-term nutritional supplement approach using fisetin and DHA. These compounds are derived from natural sources (strawberries for fisetin, fish oil for DHA) and can be administered orally without the severe side effects of hormonal treatments, effectively substituting a harmful long-term solution with a safe alternative.
Solution Approach 2:
The patent introduces fisetin and DHA as intermediary substances that mediate between the body's natural bone metabolism processes and the therapeutic goal of preventing bone loss. These compounds act as natural mediators that stimulate osteoblast activity and inhibit osteoclast activity without directly interfering with hormonal pathways, thus avoiding the side effects of hormone replacement therapy.
2Reliability
If calcium and vitamin D supplementation is used for bone health, then bone mineralization is supported, but the treatment is insufficient for active bone formation stimulation
Solution Approach 1:
The patent combines fisetin and DHA into a single therapeutic formulation that merges two distinct mechanisms of action: fisetin stimulates osteoblast differentiation and bone formation, while DHA inhibits osteoclast activity and reduces bone resorption. This combination approach integrates both bone formation stimulation and bone loss prevention into one treatment protocol, overcoming the limitations of single-agent therapies.
Solution Approach 2:
The patent creates a composite therapeutic approach using fisetin (a flavonoid compound) and DHA (an omega-3 fatty acid), two chemically distinct substances with complementary effects on bone metabolism. This composite formulation leverages the synergistic interactions between different molecular structures to achieve enhanced therapeutic effects that neither compound could provide alone.
3Object-affected harmful factors
If existing nutritional prevention strategies are used, then basic bone health is maintained, but alternative side-effect-free solutions with enhanced efficacy are needed
Solution Approach 1:
The patent changes the fundamental parameters of nutritional supplementation by introducing specific bioactive compounds (fisetin and DHA) at optimized concentrations and ratios. Rather than using generic calcium and vitamin D supplements, the patent precisely controls the dosage and combination of fisetin and DHA to maximize therapeutic effect while maintaining safety, representing a paradigm shift from conventional nutritional support to targeted nutraceutical therapy.
Data Source
Figure 1A~1B
Figure 2A~2C
Figure 3A~3C
AI summary
The invention relates to a combination including at least (i) fisetin or one of the derivatives thereof, and (ii) docosahexaenoic acid (DHA) or one of the derivatives thereof, to be used for the treatment and/or prevention of disorders associated with bone loss and/or with an imbalance in the ratio of bone formation to resorption. The invention also relates to a composition including said combination for the use thereof as previously described.